Evidence map›Paper›PMID 35120441›Full record

ArticleBMC infectious diseases2022

Performance and utility of more highly sensitive malaria rapid diagnostic tests.

Hannah C Slater, Xavier C Ding, Sophia Knudson, Daniel J Bridges, Hawela Moonga, Neil J Saad, Martin De Smet, Adam Bennett, Sabine Dittrich, Laurence Slutsker and 1 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05757167 (Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity), which is not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05757167 phase4active not recruitingnot on this mapstarted 2023, after this paper: background citation

Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity

TypeinterventionalSponsorDuke UniversityRan2023 to 2026Enrolled2,174ConditionsMalaria,Falciparum, Malaria in Pregnancy, Malaria in Childbirth, PregnancyArmsMalaria High-Sensitivity Rapid Diagnostic Test (HS-RDT), Artemether-lumefantrine (AL)
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 43 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Diagnostic performance of NxTekMalaria journal · 2023
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 4 countries.

Hannah C SlaterDiagnostics Program, PATH, Seattle, WA, USA. hslater@path.org.ORCID http://orcid.org/0000-0003-4291-7899
Xavier C DingFoundation for Innovative New Diagnostics, Geneva, Switzerland.
Sophia KnudsonDiagnostics Program, PATH, Seattle, WA, USA.
Daniel J BridgesPATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
Hawela MoongaNational Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia.
Neil J SaadMédecins Sans Frontières, Phnom Penh, Preah Vihear, Cambodia.
Martin De SmetMédecins Sans Frontières, Brussels, Belgium.
Adam BennettMalaria and Neglected Tropical Diseases, PATH, Seattle, WA, USA.
Sabine DittrichFoundation for Innovative New Diagnostics, Geneva, Switzerland.
Laurence SlutskerMalaria and Neglected Tropical Diseases, PATH, Seattle, WA, USA.
Gonzalo J DomingoDiagnostics Program, PATH, Seattle, WA, USA.
Program for Appropriate Technology in Health · USFIND · CHMédecins Sans Frontières · BEMinistry of Health · ZMNational HIV/AIDS/STI/TB Council · ZM

Funding

Bill and Melinda Gates Foundation OPP1135840
6 · The paper itself

Abstract

backgroundA new more highly sensitive rapid diagnostic test (HS-RDT) for Plasmodium falciparum malaria (Alere™/Abbott Malaria Ag P.f RDT [05FK140], now called NxTek™ Eliminate Malaria Ag Pf) was launched in 2017. The test has already been used in many research studies in a wide range of geographies and use cases.

methodsIn this study, we collate all published and available unpublished studies that use the HS-RDT and assess its performance in (i) prevalence surveys, (ii) clinical diagnosis, (iii) screening pregnant women, and (iv) active case detection. Two individual-level data sets from asymptomatic populations are used to fit logistic regression models to estimate the probability of HS-RDT positivity based on histidine-rich protein 2 (HRP2) concentration and parasite density. The performance of the HS-RDT in prevalence surveys is estimated by calculating the sensitivity and positive proportion in comparison to polymerase chain reaction (PCR) and conventional malaria RDTs.

resultsWe find that across 18 studies, in prevalence surveys, the mean sensitivity of the HS-RDT is estimated to be 56.1% (95% confidence interval [CI] 46.9-65.4%) compared to 44.3% (95% CI 32.6-56.0%) for a conventional RDT (co-RDT) when using nucleic acid amplification techniques as the reference standard. In studies where prevalence was estimated using both the HS-RDT and a co-RDT, we found that prevalence was on average 46% higher using a HS-RDT compared to a co-RDT. For use in clinical diagnosis and screening pregnant women, the HS-RDT was not significantly more sensitive than a co-RDT.

conclusionsOverall, the evidence presented here suggests that the HS-RDT is more sensitive in asymptomatic populations and could provide a marginal improvement in clinical diagnosis and screening pregnant women. Although the HS-RDT has limited temperature stability and shelf-life claims compared to co-RDTs, there is no evidence to suggest, given this test has the same cost as current RDTs, it would have any negative impacts in terms of malaria misdiagnosis if it were widely used in all four population groups explored here.

Indexed as

MalariaMalaria, FalciparumAntigens, ProtozoanCross-Sectional StudiesDiagnostic Tests, RoutineFemaleHumansPlasmodium falciparumPregnancyProtozoan ProteinsSensitivity and SpecificityAntigens, ProtozoanProtozoan ProteinsCross-sectional surveysHS-RDTMalaria diagnosisRapid diagnostic test

Identifiers

PMID35120441
PMCPMC8815208
OpenAlexW4226207949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.